| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Air Pollution | 8 | 2020 | 42 | 2.500 |
Why?
|
| Cannabis | 7 | 2022 | 78 | 2.070 |
Why?
|
| Vehicle Emissions | 6 | 2018 | 23 | 1.420 |
Why?
|
| Environmental Exposure | 6 | 2015 | 115 | 1.410 |
Why?
|
| Air Pollutants | 6 | 2018 | 52 | 1.350 |
Why?
|
| Humans | 71 | 2023 | 18430 | 1.210 |
Why?
|
| Ozone | 3 | 2015 | 11 | 1.130 |
Why?
|
| Pregnant Women | 4 | 2021 | 44 | 1.090 |
Why?
|
| Female | 49 | 2023 | 13136 | 1.030 |
Why?
|
| Hallucinogens | 2 | 2022 | 23 | 0.990 |
Why?
|
| Pregnancy | 17 | 2023 | 1516 | 0.960 |
Why?
|
| Vital Capacity | 3 | 2008 | 35 | 0.910 |
Why?
|
| Forced Expiratory Volume | 3 | 2008 | 69 | 0.900 |
Why?
|
| Methamphetamine | 1 | 2022 | 3 | 0.860 |
Why?
|
| Cocaine | 1 | 2022 | 6 | 0.860 |
Why?
|
| Adiposity | 3 | 2019 | 67 | 0.860 |
Why?
|
| Soot | 6 | 2014 | 7 | 0.840 |
Why?
|
| Middle Aged | 38 | 2022 | 8284 | 0.840 |
Why?
|
| Aged | 34 | 2021 | 6417 | 0.830 |
Why?
|
| Breast Neoplasms | 8 | 2023 | 1037 | 0.790 |
Why?
|
| Male | 38 | 2022 | 10440 | 0.740 |
Why?
|
| Mammography | 3 | 2020 | 174 | 0.730 |
Why?
|
| HIV Infections | 6 | 2021 | 695 | 0.670 |
Why?
|
| Regression Analysis | 3 | 2015 | 319 | 0.660 |
Why?
|
| Breast | 3 | 2023 | 84 | 0.660 |
Why?
|
| Spatial Analysis | 2 | 2015 | 12 | 0.650 |
Why?
|
| Substance-Related Disorders | 3 | 2022 | 439 | 0.650 |
Why?
|
| Aging | 6 | 2014 | 165 | 0.640 |
Why?
|
| Adult | 29 | 2023 | 7910 | 0.620 |
Why?
|
| Cardiovascular Diseases | 4 | 2019 | 630 | 0.590 |
Why?
|
| Prenatal Care | 5 | 2023 | 134 | 0.590 |
Why?
|
| California | 15 | 2022 | 2365 | 0.580 |
Why?
|
| Menarche | 1 | 2017 | 30 | 0.580 |
Why?
|
| Child Health | 1 | 2017 | 34 | 0.570 |
Why?
|
| Self Report | 5 | 2022 | 256 | 0.570 |
Why?
|
| Particulate Matter | 2 | 2014 | 29 | 0.570 |
Why?
|
| Prostatic Neoplasms | 4 | 2020 | 298 | 0.560 |
Why?
|
| Developmental Disabilities | 1 | 2017 | 53 | 0.560 |
Why?
|
| Environmental Monitoring | 2 | 2014 | 26 | 0.550 |
Why?
|
| Retrospective Studies | 18 | 2022 | 2550 | 0.540 |
Why?
|
| Tobacco Smoking | 3 | 2021 | 20 | 0.540 |
Why?
|
| Inflammation | 3 | 2013 | 63 | 0.530 |
Why?
|
| Survival Analysis | 2 | 2017 | 226 | 0.530 |
Why?
|
| Climate Change | 1 | 2015 | 2 | 0.520 |
Why?
|
| Blood Pressure | 3 | 2022 | 310 | 0.510 |
Why?
|
| Aged, 80 and over | 14 | 2021 | 2003 | 0.510 |
Why?
|
| Autism Spectrum Disorder | 1 | 2017 | 164 | 0.480 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2023 | 414 | 0.460 |
Why?
|
| Bias | 1 | 2014 | 111 | 0.460 |
Why?
|
| Retroelements | 1 | 2013 | 1 | 0.440 |
Why?
|
| Cohort Studies | 12 | 2021 | 2672 | 0.440 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 26 | 0.430 |
Why?
|
| DNA Methylation | 1 | 2013 | 42 | 0.430 |
Why?
|
| Alcohol Drinking | 3 | 2021 | 375 | 0.420 |
Why?
|
| Longitudinal Studies | 9 | 2022 | 724 | 0.420 |
Why?
|
| Pregnancy, Ectopic | 2 | 2022 | 6 | 0.410 |
Why?
|
| Colorectal Neoplasms | 4 | 2020 | 656 | 0.400 |
Why?
|
| Lung Neoplasms | 3 | 2021 | 259 | 0.400 |
Why?
|
| Cross-Sectional Studies | 7 | 2023 | 1360 | 0.390 |
Why?
|
| Endothelium | 1 | 2011 | 1 | 0.380 |
Why?
|
| Nicotine | 2 | 2022 | 47 | 0.380 |
Why?
|
| Young Adult | 11 | 2020 | 2518 | 0.380 |
Why?
|
| Group Practice | 2 | 2020 | 26 | 0.360 |
Why?
|
| Incidence | 6 | 2022 | 1314 | 0.360 |
Why?
|
| Breast Density | 2 | 2020 | 31 | 0.350 |
Why?
|
| Phacoemulsification | 2 | 2021 | 3 | 0.340 |
Why?
|
| Sarcopenia | 2 | 2020 | 11 | 0.330 |
Why?
|
| Marijuana Smoking | 2 | 2020 | 50 | 0.330 |
Why?
|
| Muscle, Skeletal | 2 | 2020 | 32 | 0.330 |
Why?
|
| Marijuana Use | 2 | 2021 | 33 | 0.330 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2023 | 412 | 0.330 |
Why?
|
| Pregnancy Complications | 3 | 2020 | 193 | 0.330 |
Why?
|
| Biomarkers | 4 | 2020 | 308 | 0.310 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2021 | 760 | 0.310 |
Why?
|
| Risk Factors | 12 | 2021 | 3449 | 0.310 |
Why?
|
| Antioxidants | 1 | 2008 | 40 | 0.310 |
Why?
|
| Colonic Neoplasms | 2 | 2020 | 157 | 0.310 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2007 | 2 | 0.300 |
Why?
|
| Diabetes, Gestational | 2 | 2022 | 339 | 0.300 |
Why?
|
| Obesity | 3 | 2017 | 855 | 0.290 |
Why?
|
| Delivery of Health Care, Integrated | 4 | 2021 | 567 | 0.290 |
Why?
|
| Bayes Theorem | 3 | 2022 | 69 | 0.290 |
Why?
|
| Risk Assessment | 6 | 2020 | 1143 | 0.280 |
Why?
|
| Case-Control Studies | 5 | 2022 | 1173 | 0.270 |
Why?
|
| Cannabinoid Receptor Agonists | 2 | 2022 | 8 | 0.260 |
Why?
|
| Analgesics | 2 | 2022 | 28 | 0.260 |
Why?
|
| United States | 11 | 2021 | 4164 | 0.250 |
Why?
|
| Body Composition | 3 | 2020 | 82 | 0.250 |
Why?
|
| Ethanol | 2 | 2022 | 23 | 0.250 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2007 | 182 | 0.250 |
Why?
|
| Treatment Refusal | 1 | 2015 | 38 | 0.250 |
Why?
|
| Smoking | 3 | 2021 | 494 | 0.240 |
Why?
|
| Computer Simulation | 2 | 2015 | 85 | 0.240 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2020 | 208 | 0.240 |
Why?
|
| Attitude to Health | 1 | 2015 | 177 | 0.220 |
Why?
|
| Colectomy | 2 | 2020 | 27 | 0.220 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 2021 | 16 | 0.220 |
Why?
|
| Cognition | 3 | 2014 | 82 | 0.220 |
Why?
|
| Hypertension | 2 | 2022 | 524 | 0.220 |
Why?
|
| Residence Characteristics | 2 | 2018 | 256 | 0.220 |
Why?
|
| Transcriptome | 1 | 2023 | 22 | 0.220 |
Why?
|
| Triclosan | 1 | 2022 | 4 | 0.210 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 3 | 2011 | 8 | 0.210 |
Why?
|
| Intercellular Adhesion Molecule-1 | 3 | 2011 | 9 | 0.210 |
Why?
|
| Intimate Partner Violence | 1 | 2023 | 12 | 0.210 |
Why?
|
| Body Mass Index | 2 | 2017 | 974 | 0.210 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2022 | 15 | 0.210 |
Why?
|
| Postoperative Complications | 2 | 2021 | 103 | 0.210 |
Why?
|
| Dietary Approaches To Stop Hypertension | 1 | 2022 | 4 | 0.210 |
Why?
|
| Trees | 1 | 2022 | 3 | 0.210 |
Why?
|
| Early Detection of Cancer | 4 | 2020 | 526 | 0.210 |
Why?
|
| Cancer Survivors | 2 | 2020 | 89 | 0.210 |
Why?
|
| Prevalence | 6 | 2020 | 911 | 0.200 |
Why?
|
| Delayed Diagnosis | 2 | 2020 | 19 | 0.200 |
Why?
|
| Dermatologists | 1 | 2021 | 2 | 0.200 |
Why?
|
| Dermatology | 1 | 2021 | 6 | 0.200 |
Why?
|
| Mentoring | 1 | 2022 | 28 | 0.200 |
Why?
|
| Intrauterine Devices | 1 | 2021 | 11 | 0.200 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 11 | 0.190 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 444 | 0.190 |
Why?
|
| Keratosis, Actinic | 1 | 2021 | 5 | 0.190 |
Why?
|
| Cataract | 1 | 2021 | 10 | 0.190 |
Why?
|
| Parks, Recreational | 1 | 2022 | 38 | 0.190 |
Why?
|
| Marijuana Abuse | 1 | 2021 | 41 | 0.190 |
Why?
|
| Immunity | 1 | 2020 | 6 | 0.190 |
Why?
|
| Molecular Epidemiology | 1 | 2021 | 44 | 0.190 |
Why?
|
| Legislation, Drug | 1 | 2021 | 10 | 0.190 |
Why?
|
| Colonoscopy | 2 | 2020 | 268 | 0.190 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2022 | 142 | 0.190 |
Why?
|
| Carcinogenesis | 1 | 2020 | 9 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 55 | 0.180 |
Why?
|
| Radiography, Thoracic | 1 | 2020 | 19 | 0.180 |
Why?
|
| Patient Preference | 1 | 2020 | 45 | 0.180 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 64 | 0.180 |
Why?
|
| Bridged-Ring Compounds | 1 | 2020 | 4 | 0.180 |
Why?
|
| Taxoids | 1 | 2020 | 8 | 0.180 |
Why?
|
| Life Expectancy | 1 | 2020 | 33 | 0.180 |
Why?
|
| Operative Time | 1 | 2019 | 4 | 0.180 |
Why?
|
| Colonic Polyps | 1 | 2020 | 35 | 0.180 |
Why?
|
| Robotic Surgical Procedures | 1 | 2019 | 6 | 0.180 |
Why?
|
| Child | 4 | 2022 | 2571 | 0.180 |
Why?
|
| Anthracyclines | 1 | 2020 | 16 | 0.180 |
Why?
|
| Genome-Wide Association Study | 4 | 2023 | 252 | 0.180 |
Why?
|
| Vaccination | 1 | 2015 | 674 | 0.170 |
Why?
|
| Hysterectomy | 1 | 2019 | 30 | 0.170 |
Why?
|
| Precancerous Conditions | 1 | 2020 | 48 | 0.170 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 95 | 0.170 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2019 | 4 | 0.170 |
Why?
|
| Contraceptive Agents, Female | 1 | 2019 | 12 | 0.170 |
Why?
|
| Tissue Distribution | 1 | 2019 | 6 | 0.170 |
Why?
|
| Contraceptives, Oral | 1 | 2019 | 26 | 0.170 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 65 | 0.170 |
Why?
|
| Autistic Disorder | 1 | 2020 | 105 | 0.170 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2019 | 19 | 0.170 |
Why?
|
| Anxiety Disorders | 1 | 2020 | 93 | 0.170 |
Why?
|
| Dementia | 1 | 2021 | 105 | 0.160 |
Why?
|
| Treatment Outcome | 5 | 2021 | 1296 | 0.160 |
Why?
|
| Anxiety | 1 | 2020 | 156 | 0.160 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2020 | 159 | 0.160 |
Why?
|
| Fractures, Bone | 1 | 2019 | 91 | 0.160 |
Why?
|
| Survival Rate | 2 | 2017 | 269 | 0.160 |
Why?
|
| Geographic Mapping | 1 | 2018 | 4 | 0.160 |
Why?
|
| Smoking Cessation | 1 | 2020 | 199 | 0.160 |
Why?
|
| Cities | 1 | 2018 | 29 | 0.150 |
Why?
|
| Continental Population Groups | 1 | 2020 | 315 | 0.150 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 1389 | 0.150 |
Why?
|
| Alaska Natives | 1 | 2017 | 5 | 0.150 |
Why?
|
| Child, Preschool | 2 | 2017 | 1478 | 0.150 |
Why?
|
| Indians, North American | 1 | 2017 | 50 | 0.150 |
Why?
|
| Depressive Disorder | 1 | 2020 | 231 | 0.150 |
Why?
|
| Genotype | 3 | 2021 | 253 | 0.150 |
Why?
|
| Comorbidity | 4 | 2020 | 619 | 0.150 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2017 | 2 | 0.150 |
Why?
|
| Boston | 3 | 2012 | 37 | 0.150 |
Why?
|
| Visual Acuity | 1 | 2017 | 22 | 0.150 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 321 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 50 | 0.140 |
Why?
|
| Medication Adherence | 1 | 2020 | 267 | 0.140 |
Why?
|
| Models, Statistical | 2 | 2015 | 185 | 0.140 |
Why?
|
| Linear Models | 2 | 2014 | 243 | 0.140 |
Why?
|
| Logistic Models | 2 | 2021 | 962 | 0.140 |
Why?
|
| Genetic Testing | 1 | 2017 | 89 | 0.140 |
Why?
|
| Mental Health | 1 | 2017 | 168 | 0.130 |
Why?
|
| Risk | 1 | 2017 | 552 | 0.130 |
Why?
|
| Neoplasms | 1 | 2020 | 457 | 0.130 |
Why?
|
| Data Interpretation, Statistical | 1 | 2015 | 83 | 0.130 |
Why?
|
| Forecasting | 1 | 2015 | 80 | 0.130 |
Why?
|
| Depression | 1 | 2020 | 518 | 0.120 |
Why?
|
| Spacecraft | 1 | 2014 | 1 | 0.120 |
Why?
|
| Particle Size | 1 | 2014 | 4 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 249 | 0.120 |
Why?
|
| DNA, Mitochondrial | 1 | 2014 | 2 | 0.120 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 1269 | 0.120 |
Why?
|
| New England | 1 | 2014 | 13 | 0.120 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 399 | 0.120 |
Why?
|
| Mass Screening | 4 | 2021 | 690 | 0.120 |
Why?
|
| Cognition Disorders | 1 | 2014 | 32 | 0.120 |
Why?
|
| Adolescent | 5 | 2020 | 3798 | 0.120 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2013 | 2 | 0.110 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2013 | 8 | 0.110 |
Why?
|
| Base Sequence | 1 | 2013 | 20 | 0.110 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 743 | 0.110 |
Why?
|
| Gene Expression | 1 | 2013 | 23 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 53 | 0.110 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 337 | 0.110 |
Why?
|
| Membrane Proteins | 1 | 2013 | 40 | 0.110 |
Why?
|
| Algorithms | 1 | 2014 | 241 | 0.110 |
Why?
|
| Inhalation Exposure | 1 | 2012 | 5 | 0.100 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2012 | 9 | 0.100 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2011 | 1 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2011 | 17 | 0.100 |
Why?
|
| Time Factors | 3 | 2021 | 1136 | 0.090 |
Why?
|
| Pandemics | 2 | 2023 | 292 | 0.090 |
Why?
|
| Prostate-Specific Antigen | 2 | 2020 | 77 | 0.090 |
Why?
|
| Respiration Disorders | 1 | 2009 | 5 | 0.080 |
Why?
|
| Blood Glucose | 2 | 2021 | 346 | 0.080 |
Why?
|
| Heme Oxygenase-1 | 1 | 2008 | 1 | 0.080 |
Why?
|
| Glutathione Transferase | 1 | 2008 | 13 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 131 | 0.080 |
Why?
|
| Oxidative Stress | 1 | 2008 | 10 | 0.080 |
Why?
|
| Patient Readmission | 2 | 2020 | 162 | 0.080 |
Why?
|
| Registries | 2 | 2020 | 490 | 0.080 |
Why?
|
| Bronchial Provocation Tests | 1 | 2007 | 1 | 0.080 |
Why?
|
| Methacholine Chloride | 1 | 2007 | 1 | 0.080 |
Why?
|
| Likelihood Functions | 1 | 2007 | 48 | 0.070 |
Why?
|
| Spirometry | 1 | 2007 | 65 | 0.070 |
Why?
|
| Prognosis | 2 | 2020 | 624 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2021 | 1314 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 131 | 0.070 |
Why?
|
| Electronic Health Records | 2 | 2019 | 747 | 0.070 |
Why?
|
| Veterans | 1 | 2007 | 138 | 0.070 |
Why?
|
| Topography, Medical | 1 | 2015 | 5 | 0.060 |
Why?
|
| Utilization Review | 1 | 2015 | 56 | 0.060 |
Why?
|
| Immunization, Secondary | 1 | 2015 | 64 | 0.060 |
Why?
|
| Primary Health Care | 2 | 2021 | 848 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2015 | 96 | 0.060 |
Why?
|
| Phenol | 1 | 2022 | 4 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2023 | 34 | 0.050 |
Why?
|
| Whole Exome Sequencing | 1 | 2022 | 8 | 0.050 |
Why?
|
| Exome | 1 | 2022 | 25 | 0.050 |
Why?
|
| Massachusetts | 2 | 2014 | 99 | 0.050 |
Why?
|
| Benzhydryl Compounds | 1 | 2022 | 23 | 0.050 |
Why?
|
| Phenols | 1 | 2022 | 34 | 0.050 |
Why?
|
| Phenotype | 1 | 2022 | 148 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 65 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 392 | 0.050 |
Why?
|
| Cannabinoids | 1 | 2021 | 6 | 0.050 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2021 | 12 | 0.050 |
Why?
|
| Prednisolone | 1 | 2021 | 3 | 0.050 |
Why?
|
| Contraception | 1 | 2021 | 25 | 0.050 |
Why?
|
| Prescriptions | 1 | 2021 | 28 | 0.050 |
Why?
|
| Lipids | 1 | 2021 | 78 | 0.050 |
Why?
|
| Lactation | 1 | 2021 | 50 | 0.050 |
Why?
|
| Postpartum Period | 1 | 2021 | 93 | 0.050 |
Why?
|
| Genetic Pleiotropy | 1 | 2020 | 9 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 68 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2020 | 19 | 0.050 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2020 | 24 | 0.050 |
Why?
|
| Image-Guided Biopsy | 1 | 2020 | 2 | 0.050 |
Why?
|
| Morbidity | 1 | 2020 | 62 | 0.050 |
Why?
|
| SEER Program | 1 | 2020 | 101 | 0.050 |
Why?
|
| Intestinal Mucosa | 1 | 2020 | 6 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 49 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 120 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2020 | 37 | 0.040 |
Why?
|
| Colon | 1 | 2020 | 21 | 0.040 |
Why?
|
| Self Medication | 1 | 2020 | 5 | 0.040 |
Why?
|
| Psychological Trauma | 1 | 2020 | 6 | 0.040 |
Why?
|
| Life Style | 1 | 2022 | 342 | 0.040 |
Why?
|
| Reoperation | 1 | 2019 | 30 | 0.040 |
Why?
|
| Age of Onset | 1 | 2020 | 82 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 146 | 0.040 |
Why?
|
| Levonorgestrel | 1 | 2019 | 5 | 0.040 |
Why?
|
| Breast Feeding | 1 | 2021 | 133 | 0.040 |
Why?
|
| Educational Status | 1 | 2020 | 205 | 0.040 |
Why?
|
| Length of Stay | 1 | 2020 | 183 | 0.040 |
Why?
|
| Continuity of Patient Care | 1 | 2021 | 112 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2022 | 251 | 0.040 |
Why?
|
| Progestins | 1 | 2019 | 28 | 0.040 |
Why?
|
| Metformin | 1 | 2020 | 61 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2020 | 119 | 0.040 |
Why?
|
| Homosexuality, Male | 1 | 2019 | 38 | 0.040 |
Why?
|
| Sigmoidoscopy | 1 | 2019 | 67 | 0.040 |
Why?
|
| Machine Learning | 1 | 2019 | 44 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2019 | 178 | 0.040 |
Why?
|
| Glycated Hemoglobin A | 1 | 2020 | 233 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2020 | 147 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2020 | 217 | 0.040 |
Why?
|
| Adenoma | 1 | 2019 | 100 | 0.040 |
Why?
|
| European Continental Ancestry Group | 1 | 2020 | 554 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 333 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 3 | 0.040 |
Why?
|
| Substance Abuse Detection | 1 | 2017 | 19 | 0.040 |
Why?
|
| Leucovorin | 1 | 2017 | 5 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2019 | 154 | 0.040 |
Why?
|
| Organ Size | 1 | 2017 | 16 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 51 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2017 | 12 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 73 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 83 | 0.040 |
Why?
|
| Withholding Treatment | 1 | 2017 | 26 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 100 | 0.040 |
Why?
|
| Pseudophakia | 1 | 2017 | 2 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2017 | 16 | 0.040 |
Why?
|
| Refractive Errors | 1 | 2017 | 7 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2017 | 167 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 160 | 0.040 |
Why?
|
| Biometry | 1 | 2017 | 13 | 0.040 |
Why?
|
| Oncologists | 1 | 2017 | 7 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2020 | 468 | 0.040 |
Why?
|
| Age Factors | 1 | 2019 | 965 | 0.040 |
Why?
|
| Cause of Death | 1 | 2017 | 185 | 0.030 |
Why?
|
| Outcome Assessment (Health Care) | 1 | 2017 | 254 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 327 | 0.030 |
Why?
|
| Managed Care Programs | 1 | 2017 | 347 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 661 | 0.030 |
Why?
|
| Haplotypes | 1 | 2014 | 43 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2014 | 38 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 78 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 350 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2013 | 2 | 0.030 |
Why?
|
| Hemochromatosis Protein | 1 | 2013 | 8 | 0.030 |
Why?
|
| Sulfates | 1 | 2011 | 1 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 23 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 32 | 0.020 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2012 | 126 | 0.020 |
Why?
|
| Health Surveys | 1 | 2012 | 269 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2012 | 185 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2011 | 51 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2009 | 13 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2009 | 58 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 530 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 199 | 0.020 |
Why?
|
| Asthma | 1 | 2009 | 390 | 0.020 |
Why?
|